Navigation Links
SpectraScience CEO Jim Hitchin Featured in Interview With The Wall Street Transcript
Date:5/6/2009

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today announced that The Wall Street Transcript has published an in-depth interview with Chief Executive Officer Jim Hitchin. The interview, in its entirety, is available on the company's website at http://www.spectrascience.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/Wall%20Street%20Transcript.pdf

Mr. Hitchin said, "Each year there are literally hundreds of thousands of cases of colorectal, cervical and esophageal cancer which, because they are not diagnosed or caught early enough, result in higher mortality rates and higher costs. Our technology enables physicians to more accurately diagnose these diseases, and to do so at an earlier stage. This is critical to reducing deaths from cancer and to reducing overall costs to the healthcare system."

SpectraScience's technology provides the healthcare community with the promise of a higher degree of objectivity and sensitivity in the cancer screening process for colon cancer and cervical cancer. It is also undergoing clinical trials for an esophageal cancer screening application.

During the interview, Mr. Hitchin also reiterated that the company is focusing all resources in sales, adding that it has a competitive advantage from a technology standpoint and that there are no direct competitors to its cancer screening platforms. He emphasized that the chance to detect cancers early, or much earlier than is currently the case, means more people are going to live longer.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

    Contact:
    SpectraScience, Inc.                     Investor Relations
    Jim Hitchin, Chief Executive Officer     Hayden Communications
    (858) 847-0200  x 201                    Todd Pitcher
                                             (858)-518-1387

                                             Media Relations
                                             Gitenstein & Assadi PR
                                             Susan Assadi
                                             (800) 922-8792


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
2. SpectraScience Strengthens Leadership Team With Four Key Hires
3. Jim Dorst Joins SpectraScience as CFO
4. SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors
5. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on WallStreetCorner.com
6. Histogen Featured on Economic Report Television Series
7. Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal
8. Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference
9. BOXX Personal Supercomputer for Research Scientists Featured at SC08
10. ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
11. Former Speaker of the House Newt Gingrich Featured Wednesday
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):